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Combination Immunotropic Therapy of Atopic Dermatitis in Children: Cost-Benefit Analysis Vladislava Derkach Peoples' Friendship University of Russia, Moscow, Russia. RATIONALE: The study was aimed at a cost-benefit analysis (CBA) of various immunotherapy (IT) programmes (Ps) for children (Ch) with AD. METHODS: 94 Ch 3-18 ages with AD having lasted for 1-15 years were examined. All the patients received routine clinical and immuno-allergological examinations. The treatment was conducted in 2 stages: background therapy (BT) and IT. Ch were divided into 3 groups (G): IG (n530) received immunomodulator (IM) on a step-by-step basis in the course dose of 20 mg; IIG (n531) received an accelerated course of parenteral allergen-specific IT (PASIT); IIIG (n533) -a combination IT (CIT) -IM+PASIT at an accelerated pace was applied. The quality of life (QOL) of Ch with AD was assessed using the Dermatology Specific Quality of Life (DSQL) questionnaire. The CBA was conducted with due regard to a specific character of the disease, the age composition of the G examined during a current year. RESULTS: The best ratio of high therapeutic effect was recorded in the III G, in which CITwas applied -88.064.59%. In the IIG, in which PASITwas applied, a high percentage of infectious complications overlay was recorded what influenced the QOL of Ch with AD. In the IG receiving IM, the therapeutic effect was the lowest. CONCLUSIONS: Including CIT in the AD treatment Ps makes it possible to monitor the disease better, a percentage of side effects being low; moreover, it reduces expenses for BT and provides a high level of QOL. RATIONALE: Contact reactions to allergens and non-classical allergen toxicants such as trimellitic anhydride (TMA) are accompanied by the specific accumulation of eosinophils (and associated eosinophil degranulation), localized skin inflammation, and concomitant increases in sitespecific itch responses. We have recently shown that TMA-induced skin inflammation as well as increases in dermal sensory innervation and the concomitant increase in itching were each eosinophil-dependent events. This demonstrates that a necessary link exists between eosinophils and allergen-induced skin inflammation but does not implicate responsible mechanism. METHODS: Wild type (BALB/c), eosinophil deficient PHIL, and eosinophil peroxidase (EPX) as well as major basic protein (MBP-1) knockout mice were used in a TMA contact hypersensitivity model. High definition videography was used to record the extent of induced itching, prior to measuring local inflammation and the recovery of tissue biopsies for gene expression, histology, immunohistochemistry staining, and imaging of skin innervation. RESULTS: EPX knockout mice displayed decreases the skin inflammation (i.e., decreases in eosinophil accumulation, mast cell activation, and skin thickness) that were similar to the reduced inflammatory events (relative to wild type controls) occurring in eosinophil deficient PHIL mice. More importantly, these mice also displayed decreases in itching. Significantly, MBP-1 knockout mice showed no difference in any of these parameters compared with wild type mice, demonstrating differential effector functions mediated by the release of specific secondary granule proteins. CONCLUSIONS: The release of EPX (but not MBP-1) by skin eosinophils appears to be a causative mechanism contributing to the inflammation and itching that occurs following exposure to the nonclassical allergen TMA.
